Jörn Aldag
Chief Executive Officer at HOOKIPA PHARMA INC.
Net worth: 86 793 $ as of 2024-04-29
Jörn Aldag active positions
| Companies | Position | Start | End |
|---|---|---|---|
| HOOKIPA PHARMA INC. | Director/Board Member | 2017-11-30 | - |
| Chief Executive Officer | 2016-05-31 | - | |
| IDORSIA LTD | Director/Board Member | 2020-05-12 | - |
| DESERTEC Foundation | Director/Board Member | 2010-06-22 | - |
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Chief Executive Officer | 2016-06-19 | - |
GeneSpire Srl
 GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy. | Chairman | - | - |
Idorsia Pharmaceuticals Ltd.
 Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Director/Board Member | 2020-05-12 | - |
Career history of Jörn Aldag
Former positions of Jörn Aldag
| Companies | Position | Start | End |
|---|---|---|---|
| COGENT BIOSCIENCES, INC. | Director/Board Member | 2016-02-08 | 2020-07-05 |
| Independent Dir/Board Member | 2016-02-08 | 2020-07-05 | |
| MOLECULAR PARTNERS AG | Chairman | 2006-12-31 | 2018-04-17 |
G7 Therapeutics AG
 G7 Therapeutics AG Pharmaceuticals: MajorHealth Technology G7 Therapeutics AG develops GPCRs for the design of novel medicine. It plays a central role in cellular responses to a diverse array of signals including neurotransmitters, hormones and metabolites, giving this class of proteins enormous pharmacological relevance. The company was founded by Lutz Kummer and Jörn Aldag and is headquartered in Schlieren, Switzerland. | Founder | 2012-12-31 | 2015-12-31 |
| ░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░ ░░░░░ ░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░ ░░░░░░░░░░░░░░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | - | - |
| ░░░░░░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Training of Jörn Aldag
| Harvard Business School | Undergraduate Degree |
Statistics
International
| Switzerland | 5 |
| Germany | 5 |
| United States | 4 |
Operational
| Chief Executive Officer | 5 |
| Director/Board Member | 5 |
| Chairman | 2 |
Sectoral
| Health Technology | 11 |
| Finance | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 6 |
|---|---|
| MOLECULAR PARTNERS AG | Health Technology |
| EVOTEC SE | Health Technology |
| UNIQURE N.V. | Health Technology |
| COGENT BIOSCIENCES, INC. | Health Technology |
| HOOKIPA PHARMA INC. | Health Technology |
| IDORSIA LTD | Health Technology |
| Private companies | 8 |
|---|---|
| Treuhandanstalt | Finance |
Amsterdam Molecular Therapeutics (AMT) Holding NV
 Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | Commercial Services |
MAN Gutehoffnungshutte AG
 MAN Gutehoffnungshutte AG Wholesale DistributorsDistribution Services MAN Gutehoffnungshutte AG supplies automobile parts. The private company is based in Oberhausen, Germany. | Distribution Services |
| DESERTEC Foundation | |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | Health Technology |
G7 Therapeutics AG
G7 Therapeutics AG Pharmaceuticals: MajorHealth Technology G7 Therapeutics AG develops GPCRs for the design of novel medicine. It plays a central role in cellular responses to a diverse array of signals including neurotransmitters, hormones and metabolites, giving this class of proteins enormous pharmacological relevance. The company was founded by Lutz Kummer and Jörn Aldag and is headquartered in Schlieren, Switzerland. | Health Technology |
GeneSpire Srl
GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy. | Health Technology |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | Health Technology |
- Stock Market
- Insiders
- Jörn Aldag
- Experience